Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
This study will evaluate the efficacy and safety data of AZD8871 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03645434
- Testing
- AZD8871, Anoro® Ellipta®
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
COPD
Dose of Corticosteroids in COPD
COPD (chronic obstructive pulmonary disease) is a long-lasting lung disease usually caused by long-term smoking. COPD can get worse, making people sick enough to need hospitalization.
- Trial name
- DOSE (NCT01742338)
- Testing
- Low Dose Corticosteroids, High Dose Corticosteroids
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Rutgers, The State University of New Jersey
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary…
- Trial name
- GLOW6 (NCT01604278)
- Testing
- NVA237 50 µg and indacaterol 150 µg
- Where
- 80 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 449 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, COPD
Repeat Emergency Department Visits Among Patients With Asthma and COPD
The purpose of the proposed study is to determine whether the addition of inhaled corticosteroids to treatment with oral corticosteroids and albuterol would reduce repeat emergency department (ED) visits among patients treated…
- Trial name
- NCT02499887
- Testing
- beclamethasone dipropionate, albuterol, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- State University of New York at Buffalo
Chronic Obstructive Pulmonary Disease
COPD Assessment and Management Bundle Versus Usual Care
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory (lung) disease that makes it harder to breathe over time.
- Trial name
- NCT01833026
- Testing
- Spirometry test, Levalbuterol
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Illinois Chicago
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat…
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
- Trial name
- ATALANTa (NCT03679598)
- Testing
- Alvelestat (MPH966)
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide in Peri-Operative COPD
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general…
- Trial name
- NCT01943552
- Testing
- ipratropium bromide
- Where
- 9 sites in China
- Volunteers
- 192 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
This study is being done to examine the influence of Tiotropium (good or bad) on heart function at rest and during exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00578968
- Testing
- Tiotropium
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural…
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma
- Trial name
- Aim3 (NCT00122135)
- Testing
- Values Inventory (VI)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Acute Lung Injury, Chronic Obstructive Pulmonary Disease (COPD)
Imaging of Peri-operative (periOP) Lung Injury
The aim of study is to determine if 99mTc Annexin V-128 (AxV- 128/Tc) single photon emission computed tomography (SPECT)-computed tomography (CT) can detect perioperative lung injury.
- Trial name
- NCT02978885
- Testing
- SPECT-CT imaging, AxV-128/Tc, Whipple procedure
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Graft Versus Host Disease
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD).
- Trial name
- NCT00529035
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Pulmonary Disease, Chronic Obstructive
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of…
- Trial name
- COPD nDPI (NCT01316887)
- Testing
- 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 563 people
- Sponsor
- GlaxoSmithKline
Graft Versus Host Disease, Ophthalmologic Complications
Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
This phase II clinical trial studies how well bandage lenses work in treating patients with ocular graft versus host disease. Bandage lenses may be helpful in relieving eye symptoms and damage caused by eye graft versus host…
- Trial name
- NCT01616056
- Testing
- graft versus host disease prophylaxis/therapy, questionnaire administration, optical coherence tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.